评估拉沙热动物模型中的抗病毒疗法。

Assessment of antiviral therapeutics in animal models of Lassa fever.

机构信息

Department of Medical Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada.

Zoonotic Diseases and Special Pathogens Program, National Microbiology Laboratory, Winnipeg, Manitoba, Canada.

出版信息

Curr Opin Virol. 2019 Aug;37:84-90. doi: 10.1016/j.coviro.2019.06.010. Epub 2019 Jul 26.

DOI:10.1016/j.coviro.2019.06.010

PMID:31357140

Abstract

Lassa virus (LASV) is an emerging zoonotic virus endemic in West Africa that can cause severe haemorrhagic Lassa fever (LF) in humans. LF recently gained international attention as a prominent infectious disease, leading to increasingly severe outbreaks in Nigeria over the past three years. Morbidity and mortality associated with LF disease in Nigeria continue to rise with 106 deaths reported in 2016, 143 in 2017 and 562 in 2018. Despite the significant health impact LF imposes on West Africa there are currently no FDA-approved therapeutics or vaccines available for treatment and prevention. This review focuses on the assessment and current state of LF antiviral therapeutics in animal models and their potential role in reducing disease burden throughout West Africa.

摘要

拉萨病毒（LASV）是一种在西非流行的新兴人畜共患病毒，可导致人类发生严重的出血性拉萨热（LF）。LF 最近作为一种突出的传染病引起了国际关注，在过去三年中，尼日利亚的疫情越来越严重。与尼日利亚 LF 疾病相关的发病率和死亡率持续上升，2016 年报告了 106 例死亡，2017 年报告了 143 例，2018 年报告了 562 例。尽管 LF 对西非造成了重大的健康影响，但目前尚无获得 FDA 批准的治疗药物或疫苗可用于治疗和预防。本综述重点评估了 LF 抗病毒治疗药物在动物模型中的应用现状及其在减轻整个西非疾病负担方面的潜在作用。